Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors & Methods of Cancer Treatment wit...
October 23 2014 - 8:30AM
Business Wire
-- Publication of patent applications for five
additional HMT targets broadens intellectual property estate and
demonstrates the breadth of Epizyme leadership in the field of
histone methyltransferases (HMTs) --
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical
company creating innovative personalized therapeutics for patients
with genetically defined cancers, announced today that the US
Patent and Trademark Office has granted Notices of Allowance for US
Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled
“PRMT5 Inhibitors and Uses Thereof.” The allowed claims cover
inhibitors of PRMT5 and methods of cancer treatment with PRMT5
inhibitors. PRMT5 is implicated in several cancers, including blood
cancers.
Epizyme also announced the publication of 10 patent applications
covering chemical matter targeting several additional HMTs: CARM1,
PRMT1, PRMT3, PRMT6 and PRMT8. These additional HMT targets are
implicated in a variety of solid tumors and hematologic
malignancies.
“These notices of allowance and publications further solidify
our leadership position in the HMT space, and we continue to
advance our dominant intellectual property position. Epizyme now
has patents and patent applications for 13 of the 20 prioritized
targets that comprise the Company’s pioneering HMT platform,
covering therapeutic and diagnostic methods, combination therapy
methods and pharmaceutical compositions,” said Robert Gould, Ph.D.,
President and Chief Executive Officer, Epizyme. “We believe these
patents and pending applications place us in the strongest possible
position to build our company over the long-term and accelerate our
efforts to bring life-saving drugs to patients.”
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company
creating personalized therapeutics for patients with genetically
defined cancers. Epizyme has built a proprietary product platform
that the Company uses to create small molecule inhibitors of a
96-member class of enzymes known as histone methyltransferases, or
HMTs. HMTs are part of the system of gene regulation, referred to
as epigenetics, that controls gene expression. Genetic alterations
can result in changes to the activity of HMTs, making them
oncogenic (cancer-causing). By focusing on the genetic drivers of
cancers, Epizyme's targeted science seeks to match the right
medicines with the right patients for a personalized approach to
cancer treatment.
For more information, visit www.epizyme.com and connect with us
on Twitter at @EpizymeRx.
Media/Investors:Epizyme,
Inc.Manisha Pai, 617-229-7560
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2023 to Apr 2024